Kura Oncology (NASDAQ:KURA) Shares Gap Down Following Analyst Downgrade

Kura Oncology, Inc. (NASDAQ:KURA) shares gapped down before the market opened on Thursday after Jefferies Financial Group lowered their price target on the stock from $32.00 to $28.00. The stock had previously closed at $15.91, but opened at $11.80. Jefferies Financial Group currently has a buy rating on the stock. Kura Oncology shares last traded at $9.78, with a volume of 3,092,133 shares.

KURA has been the subject of a number of other research reports. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Tuesday. Wedbush restated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Monday, November 4th. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in Kura Oncology in the third quarter worth $25,000. ProShare Advisors LLC boosted its stake in shares of Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC increased its position in shares of Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after buying an additional 1,673 shares during the period. The Manufacturers Life Insurance Company raised its stake in Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after buying an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after buying an additional 2,167 shares during the period.

Kura Oncology Stock Performance

The company has a 50-day simple moving average of $18.28 and a two-hundred day simple moving average of $19.82. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market capitalization of $811.81 million, a P/E ratio of -4.73 and a beta of 0.86.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.